1,866 results match your criteria Veno-occlusive Hepatic Disease


Hepatic disorders associated with exogenous sex steroids: MR imaging findings.

Abdom Radiol (NY) 2019 Apr 6. Epub 2019 Apr 6.

Monash Imaging, Monash Health, Melbourne, Australia.

Objective: To describe the MRI findings of the effects of exogenous sex steroids on the liver.

Findings: Estrogens, progesterone and synthetic testosterone are exogenous sex steroids that may result in a variety of liver diseases, including tumour formation and vascular disorders. These hormones are mainly administered in the form of the oral contraceptive pill (OCP) and anabolic steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01941-4DOI Listing
April 2019
2 Reads

Understanding Hepatic and Pulmonary Veno-Occlusive Disease: Similarities and Differences.

Am J Pathol 2019 Mar 26. Epub 2019 Mar 26.

INSERM UMR_S 999, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, AP-HP, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France. Electronic address:

Hepatic veno-occlusive disease (HVOD), alias sinusoidal obstruction syndrome, may develop as a complication of chemotherapy in the setting of hematopoietic stem cell transplantation. HVOD is less frequently described after exposure to chemotherapy in the nontransplant setting and can also be a complication after ingestion of toxins, such as pyrrolizidine alkaloids. Veno-occlusive disease may also affect the lungs, and it is therefore termed pulmonary veno-occlusive disease (PVOD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2019.02.007DOI Listing
March 2019
3 Reads

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Cancer 2019 Mar 28. Epub 2019 Mar 28.

Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Background: Inotuzumab ozogamicin (InO) is an antibody-drug conjugate used for adults with relapsed/refractory B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO-VATE) previously reported improved outcomes with InO versus standard-of-care (SoC) chemotherapy. This article reports the final INO-VATE results (≥2 years of follow-up) and additional analyses of patient characteristics associated with improved outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32116DOI Listing
March 2019
1 Read

Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review.

Expert Rev Gastroenterol Hepatol 2019 May 21;13(5):463-484. Epub 2019 Mar 21.

a Department of Medical and Surgical Sciences (DIMEC) , University of Bologna , Bologna , Italy.

Introduction: Veno-occlusive-disease (VOD), known also as sinusoidal-obstruction-syndrome (SOS), is one of the main complications of haematopoietic stem cell transplantation and is related to the treatment with pyrrolizidine alkaloids or other toxic agents (chemotherapy for liver-metastasis). Clinical diagnosis using the recent criteria from the European Society for Blood and Marrow Transplantation, is the reference for VOD/SOS diagnosis. However, increasing evidence suggests the emerging role of several imaging methods that could help the clinician in VOD/SOS assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1588111DOI Listing
May 2019
2 Reads

PAI-1 and protein C as early markers of veno-occlusive disease in patients treated for Wilms tumor.

Pediatr Blood Cancer 2019 Mar 13:e27695. Epub 2019 Mar 13.

Hematology Oncology Division, Department of Mother's and Child's Health, University of Padova, Padova, Italy.

Background: Hepatic veno-occlusive (VOD) disease has been described in hematopoietic stem cell transplantation (HSCT), solid tumors, and acute lymphoblastic leukemia. The incidence of VOD in Wilms tumor (WT) ranges from 1.2% to 8%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27695DOI Listing
March 2019
2 Reads

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).

Bone Marrow Transplant 2019 Feb 25. Epub 2019 Feb 25.

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

Veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) conditioning or high-dose nontransplant chemotherapy. VOD/SOS with multi-organ dysfunction (MOD) is associated with a mortality rate of > 80%. Defibrotide (25 mg/kg/day) is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post HSCT in the United States and to treat severe hepatic VOD/SOS in patients > 1 month of age in the European Union. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0474-8DOI Listing
February 2019

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Biol Blood Marrow Transplant 2019 Feb 22. Epub 2019 Feb 22.

Department of Hematology and Cell Therapy, Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation, Hôpital Saint-Antoine, Paris, France.

Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) most commonly associated with high-intensity chemotherapies. The development of VOD/SOS may be rapid and unpredictable, and the importance of identifying risk factors to facilitate prompt diagnosis and timely treatment has become increasingly recognized. The reporting of new retrospective study data for adults and children and the emergence of novel anticancer therapies that may increase the risk of VOD/SOD also necessitate updates on risk factors, as provided in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.018DOI Listing
February 2019
3 Reads

Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease.

Bone Marrow Transplant 2019 Jan 24. Epub 2019 Jan 24.

Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0432-5DOI Listing
January 2019
2 Reads

The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.

Ann Hematol 2019 Mar 21;98(3):745-752. Epub 2019 Jan 21.

Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.

Hepatic veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). We conducted this study to investigate the incidence and risk factors of hepatic VOD for patients receiving HSCT in Taiwan. We retrospectively analyzed the data from a nationwide registry for patients receiving HSCT, which was collected by the Taiwan Society of Blood and Marrow Transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03604-2DOI Listing
March 2019
5 Reads

Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.

Biol Blood Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Institute of Hematology L. and A Seràgnoli, Sant'Orsola Malpighi University Hospital, Bologna, Italy.

Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening complication affecting patients undergoing hematopoietic stem cell transplantation (HSCT). The survival rate is higher when specific therapy is initiated early; thus, improving early, noninvasive diagnosis of VOD/SOS is an important need. In an adult population undergoing HSCT, we aimed to assess the role of liver stiffness measurement (LSM), evaluated by transient elastography (TE), for diagnosing VOD/SOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.019DOI Listing
January 2019
4 Reads

No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):25-34

Division of Hematology and Bone Marrow Transplant, Mayo Clinic, Rochester, MN.

Therapeutic options for acute lymphoblastic leukemia, especially in the relapsed/refractory setting, have expanded significantly in recent times. However, this comes at the cost of toxicities: medical as well as financial. We highlight some of the unique toxicities associated with the novel agents to apprise our readers about what to expect, how to recognize them, and how to manage these toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246022PMC
November 2018
5 Reads

Pyrrolizidine alkaloid-induced alterations of prostanoid synthesis in human endothelial cells.

Chem Biol Interact 2019 Jan 19;298:104-111. Epub 2018 Nov 19.

German Federal Institute for Risk Assessment, Department Food Safety, Berlin, Germany. Electronic address:

Pyrrolizidine alkaloids (PA) are a group of secondary plant metabolites belonging to the most widely distributed natural toxins. PA intoxication of humans leads to severe liver damage, such as hepatomegaly, hepatic necrosis, fibrosis and cirrhosis. An acute consequence observed after ingestion of high amounts of PA is veno-occlusive disease (VOD) where the hepatic sinusoidal endothelial cells are affected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2018.11.007DOI Listing
January 2019
20 Reads

Is pharmacokinetic guidance a must in busulfan regimens?

Authors:
Yoshinobu Kanda

Lancet Haematol 2018 Nov;5(11):e498-e499

Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Tochigi 329-0498, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30171-6DOI Listing
November 2018

Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.

BMC Gastroenterol 2018 Oct 26;18(1):156. Epub 2018 Oct 26.

Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Donglu, Zhengzhou, 450052, Henan, China.

Background: Hepatic veno-occlusive disease (HVOD) caused by Gynura segetum has been increasingly reported in China in recent years. The aim of this retrospective study was to identify independent prognostic markers for survival in patients with Gynura segetum-induced HVOD and to evaluate the effect of anticoagulants and transjugular intrahepatic portosystemic shunt (TIPS) on survival rate.

Methods: Clinical data including symptoms, signs, imaging characteristics, laboratory test results, results of liver tissue biopsies, type of treatment during follow-up and clinical outcomes were collected. Read More

View Article

Download full-text PDF

Source
https://bmcgastroenterol.biomedcentral.com/articles/10.1186/
Publisher Site
http://dx.doi.org/10.1186/s12876-018-0879-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204041PMC
October 2018
15 Reads
2.370 Impact Factor

Treatment of hepatic veno-occlusive disease in children with N-acetylcysteine.

Pediatr Blood Cancer 2019 Feb 23;66(2):e27518. Epub 2018 Oct 23.

Parkway Cancer Centre, Gleneagles Hospital, Singapore, Singapore.

In our institution, hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) has been treated with N-acetylcysteine (NAC) since 2008-a loading dose of 150 mg/kg, followed by 12 doses of 70 mg/kg 6 hourly. Nine children were diagnosed with hepatic VOD/SOS. Hepatic VOD/SOS occurred in seven children after stem cell transplantation and two were receiving chemotherapy for Wilms tumor. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pbc.27518
Publisher Site
http://dx.doi.org/10.1002/pbc.27518DOI Listing
February 2019
4 Reads

Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.

In Vivo 2018 Nov-Dec;32(6):1409-1417

Department of Gastroenterological Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

Background: Hepatic sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease, is a form of drug-induced liver injury, the initial morphological changes associated with which occur in liver sinusoidal endothelial cells (LSECs). Recombinant human soluble thrombomodulin (rTM) is reported to have anti-inflammatory and cytoprotective effects. Therefore, we investigated the ability of rTM to protect endothelial cells and enhance their functions in a monocrotaline (MCT)-induced model of SOS. Read More

View Article

Download full-text PDF

Source
http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.11393
Publisher Site
http://dx.doi.org/10.21873/invivo.11393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365749PMC
January 2019
14 Reads

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Int J Hematol Oncol 2017 Nov 11;6(3):75-93. Epub 2017 Aug 11.

Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening and unpredictable complication of hematopoietic stem cell transplantation (HSCT). Characterized by a prothrombotic-hypofibrinolytic state, VOD/SOS typically presents with hyperbilirubinemia, ascites, weight gain and painful hepatomegaly; VOD/SOS with multiorgan failure may be associated with >80% mortality. Treatment has been mainly supportive. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/ijh-2017-0015
Publisher Site
http://dx.doi.org/10.2217/ijh-2017-0015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171967PMC
November 2017
21 Reads

Transient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients.

Mediterr J Hematol Infect Dis 2018 1;10(1):e2018049. Epub 2018 Sep 1.

Second Academic Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Hippokratio General Hospital Athens.

Sickle cell disease patients often need regular blood transfusions to improve both the quality of life and survival from the veno-occlusive complications of the disease. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with promising efficacy. This study aims to evaluate the association of liver stiffness and possible fibrosis with iron deposition and confirm the use of elastography as a validated test of responding to chelation with low cost and easy access. Read More

View Article

Download full-text PDF

Source
https://www.mjhid.org/index.php/mjhid/article/view/2018.049
Publisher Site
http://dx.doi.org/10.4084/MJHID.2018.049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131104PMC
September 2018
12 Reads

Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States.

Clin Ther 2018 Oct 7;40(10):1711-1719.e1. Epub 2018 Sep 7.

Amgen Inc, South San Francisco, California.

Purpose: The goal of this study was to evaluate the incidence, inpatient mortality, and economic burden of hepatic veno-occlusive disease (VOD) in adults with B-cell acute lymphoblastic leukemia (ALL) in the United States.

Methods: Using MarketScan Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database, data for patients with B-cell ALL from April 1, 2009, to October 31, 2016, were extracted by using diagnosis codes. VOD was identified based on clinical criteria and expert opinions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2018.08.005DOI Listing
October 2018
13 Reads

Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

Bone Marrow Transplant 2018 Sep 4. Epub 2018 Sep 4.

Department of Pediatrics, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA.

Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-018-0298-y
Publisher Site
http://dx.doi.org/10.1038/s41409-018-0298-yDOI Listing
September 2018
11 Reads

Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.

Eur J Surg Oncol 2018 10 27;44(10):1532-1538. Epub 2018 Jul 27.

Department of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Background: The prevalence of chemotherapy associated liver injuries (CALI), especially SOS (sinusoidal obstruction syndrome) and NRH (nodular regenerative hyperplasia) might be reduced since the introduction of routine use of biological agents with chemotherapy in colorectal liver metastases (CRLM).

Methods: One hundred patients with CRLM having undergone at least one liver segment resection were prospectively included, and chemotherapy data recorded. Specimens were reviewed by a single pathologist and CALI were described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.07.050DOI Listing
October 2018
6 Reads

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 3;25(1):137-144. Epub 2018 Aug 3.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

Hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), is a serious complication of hematopoietic stem cell transplantation (HSCT) with mortality in its severe form exceeding 80%. Although the incidence of VOD/SOS has fallen with contemporary transplantation practices, the increasing use of inotuzumab, the return of gemtuzumab, and the popularity of pharmacokinetic-guided high-dose busulfan may impact incidence. Early intervention with defibrotide improves survival, but prompt diagnosis can be difficult. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.039DOI Listing
January 2019
6 Reads

New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome.

Ultrasound Med Biol 2018 11 31;44(11):2171-2182. Epub 2018 Jul 31.

Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation. Clinically, SOS/VOD is characterized by hepatomegaly, right upper quadrant pain, jaundice and ascites, most often occurring within the first 3 wk after hematopoietic cell transplantation. Early therapeutic intervention is pivotal for survival in SOS/VOD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ultrasmedbio.2018.06.002DOI Listing
November 2018
2 Reads

[Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].

Zhonghua Nei Ke Za Zhi 2018 Aug;57(8):576-581

Department of Hematology, Peking University First Hospital, Beijing 100034, China.

To investigate the therapeutic effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with FLAG sequential busulfan/cyclophosphamide(Bu/Cy) conditioning regimen for refractory/relapsed acute myeloid leukemia. From February 2012 to June 2017, 21 patients with refractory/relapsed acute myeloid leukemia underwent allo-HSCT with FLAG sequential Bu/Cy conditioning regimen. Transplantation-related complications and clinical outcome were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2018.08.008DOI Listing
August 2018
1 Read

[Severe Liver Injury Due to Sinusoidal Obstruction Syndrome Induced by Oxaliplatin in a Patient with Resectable Colorectal Liver Metastases].

Gan To Kagaku Ryoho 2018 Jun;45(6):989-992

Dept. of Surgery, Aichi Kouseiren Toyota Kousei Hospital.

A 62-year-old man was diagnosed with liver metastasis of sigmoid colon cancer, which resulted in bowel obstruction. SOX plus bevacizumab therapy was administered to perform hepatectomy, after the artificial anus construction; however, substantial liver dysfunction occurred. Therefore, we only performed primary tumor resection and waited for improvement in liver function. Read More

View Article

Download full-text PDF

Source
June 2018
2 Reads

Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids.

Biomed Res Int 2018 13;2018:9804582. Epub 2018 Jun 13.

Department of Ultrasound, Air Force General Hospital of PLA, Haidian District, Beijing, 100142, China.

We retrospectively identified 89 consecutive patients from January 2004 to January 2012 to investigate efficacy of direct intrahepatic portocaval shunt (DIPS) combined with inferior vena cava (IVC) stenting for sinusoidal obstruction syndrome (SOS) associated with hepatotoxicity of pyrrolizidine alkaloids. Indications for treatment were variceal hemorrhage and/or refractory ascites. Patients were treated with DIPS plus IVC stenting (group A, n=68) or DIPS alone (group B, n=21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/9804582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020549PMC
January 2019
3 Reads

Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants.

Pediatr Transplant 2018 11 12;22(7):e13269. Epub 2018 Jul 12.

Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.

Hepatic SOS is a potentially life-threatening complication of conditioning for allogeneic HSCT. rTM is a new drug for treating DIC. We report our experience of the use of rTM as a prophylaxis against SOS in high-risk pediatric patients that underwent HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13269DOI Listing
November 2018
27 Reads

[A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation].

Zhonghua Nei Ke Za Zhi 2018 Jul;57(7):483-486

Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.

To analyze the outcome and the prognostic factors of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). A total of 797 patients receiving HSCT were analyzed retrospectively. The prophylaxis regimen of HVOD in the First Affiliated Hospital of Guangxi Medical University consisted of low molecular weight heparin and lipoprostaglandin E1 (PGE1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2018.07.003DOI Listing
July 2018
17 Reads

Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report.

BMC Res Notes 2018 Jul 3;11(1):436. Epub 2018 Jul 3.

Department of Clinical Hematology, Institut de Cancérologie Lucien Neuwirth, 108 Bis Avenue Albert Raimond, 42270, Saint Priest en Jarez, France.

Background: Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (SOS/VOD), is a potentially fatal complication of allogeneic or autologous hematopoietic stem cell transplantation. A plethora of transplant and patient-related risk factors predispose to SOS/VOD and should be taken into account for prognosis assessment as well as for adequate therapeutic intervention.

Case Presentation: We describe the case of a mantle cell lymphoma patient who developed a fulminant hepatitis following oxaliplatin-containing intensive chemotherapy and autologous transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-018-3533-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029059PMC
July 2018
10 Reads

The use of defibrotide in blood and marrow transplantation.

Blood Adv 2018 06;2(12):1495-1509

Galena Biopharma, San Ramon, CA.

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of conditioning during hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT, with a historically reported mean incidence of 13.7% post-HSCT. Typical symptoms of VOD/SOS may include hyperbilirubinemia, painful hepatomegaly, weight gain, and ascites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017008375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020812PMC
June 2018
15 Reads

Liquiritigenin and liquiritin alleviated MCT-induced HSOS by activating Nrf2 antioxidative defense system.

Toxicol Appl Pharmacol 2018 09 15;355:18-27. Epub 2018 Jun 15.

The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address:

Hepatic sinusoidal obstruction syndrome (HSOS) is a serious and life-threatening liver disease. Liquiritigenin (LG) and liquiritin (LQ) are natural flavonoids distributed in Glycyrrhizae Radix et Rhizoma (Gan-cao). This study aims to investigate the protective effect and mechanism of LG and LQ against monocrotaline (MCT)-induced HSOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.taap.2018.06.014DOI Listing
September 2018
9 Reads

Management of hepatic vein occlusive disease after liver transplantation: A case report with literature review.

Medicine (Baltimore) 2018 Jun;97(24):e11076

Department of Organ Transplantation.

Rationale: Hepatic vein occlusive disease (HVOD) is a rare complication after liver transplantation, which is characterized by nonthrombotic, fibrous obliteration of the small centrilobular hepatic veins by connective tissue and centrilobular necrosis in zone 3 of the acini. HVOD after solid organ transplantation has been reported; recently, most of these reports with limited cases have documented that acute cell rejection and immunosuppressive agents are the major causative factors. HVOD is relatively a rare complication of liver transplantation with the incidence of approximately 2%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000011076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024223PMC
June 2018
4 Reads
5.723 Impact Factor

Hepatic veno-occlusive disease following sirolimus-based immune suppression.

Bone Marrow Transplant 2018 Jun 12. Epub 2018 Jun 12.

BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.

Sirolimus-based graft vs. host disease (GVHD) prophylaxis is associated with higher incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allogeneic hematopoietic cell transplantation (HCT). However, whether the clinical manifestations and prognosis of VOD/SOS differs when diagnosed in the setting of sirolimus-based GVHD prophylaxis is not well studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0233-2DOI Listing
June 2018
5 Reads

Pattern of Vascular Involvement in Egyptian Patients with Budd-Chiari Syndrome: Relation to Etiology and Impact on Clinical Presentation.

Ann Hepatol 2018 July - August ,;17(4):638-644

Department of Radiodiagnosis and Interventional Radiology, Ain Shams University, Cairo, Abbasia, Egypt.

Introduction And Aim: Budd-Chiari syndrome (BCS) is caused by hepatic venous outflow obstruction. This work aims to analyze the pattern of vascular involvement in Egyptian patients with BCS, demonstrates its relation to etiology and shows its impact on clinical presentation.

Material And Methods: The current retrospective study was conducted at The Tropical Medicine Department, Ain Shams University on one hundred Egyptian patients with confirmed diagnosis of primary BCS who were presented to the Budd-Chiari Study Group (BCSG) from April 2014 to May 2016 by collecting clinical, laboratory and radiological data from their medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5604/01.3001.0012.0933DOI Listing
April 2019
10 Reads

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Pediatr Blood Cancer 2018 Oct 6;65(10):e27269. Epub 2018 Jun 6.

Pediatric Oncology, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially fatal complication of conditioning for hematopoietic stem cell transplantation (HSCT) but can occur after nontransplant-associated chemotherapy. Following HSCT, VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27269DOI Listing
October 2018
37 Reads
2.562 Impact Factor

Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 Sep 24;24(9):1896-1900. Epub 2018 May 24.

Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.

Sinusoidal obstruction syndrome (SOS)/hepatic veno-occlusive disease (VOD) is a well-documented complication after hematopoietic stem cell transplantation (HSCT). Transabdominal ultrasonography (US) enables the visualization of blood flow abnormalities and is therefore useful for the diagnosis of SOS/VOD. We herein prospectively evaluated accuracy of a novel US diagnostic scoring system of SOS/VOD based on US findings. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183029
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.05.025DOI Listing
September 2018
8 Reads

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Br J Haematol 2018 06 16;181(6):816-827. Epub 2018 May 16.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic stem cell transplant (HSCT) conditioning and chemotherapy. Defibrotide is approved for treatment of hepatic VOD/SOS with pulmonary or renal dysfunction [i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032999PMC
June 2018
6 Reads
4.710 Impact Factor

Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms.

J Pediatr Hematol Oncol 2018 Nov;40(8):e479-e485

Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN.

Recurrent/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell-depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent/refractory or secondary leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197927PMC
November 2018
5 Reads
0.960 Impact Factor

Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances.

Anticancer Res 2018 05;38(5):2597-2605

The George Washington University School of Medicine, Washington, DC, U.S.A.

Hepatic sinusoidal obstruction syndrome (SOS) is a rare fatal clinical entity seen following hematopoietic stem cell transplant (HSCT). It is more commonly reported to occur following allogeneic HSCT compared to autologous HSCT. Historically, it is known as hepatitis following HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12501DOI Listing
May 2018
1 Read

Hepatic veno-occlusive disease related to Gynura segetum: A case report.

Medicine (Baltimore) 2018 Apr;97(17):e0552

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine.

Introduction: Hepatic veno-occlusive disease (HVOD), as known as hepatic sinusoidal obstruction syndrome (HSOS), is an obliterative venulitis of the terminal hepatic venules, which is responsible for considerable mortality. The potential mechanism is destruction of hepatic sinusoidal endothelial cells (SEC), with sloughing and downstream occlusion of terminal hepatic venules. Here, we report a case of HVOD who have a history of ingestion of Gynura segetum for 1 month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000010552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944499PMC
April 2018
4 Reads

Hepatobiliary and Pancreatic: Obliterative portal venopathy found in Castleman disease variant of POEMS syndrome.

J Gastroenterol Hepatol 2018 Jul 24;33(7):1311. Epub 2018 Apr 24.

Department of Rheumatology and Clinical Immunology, Peking University International Hospital, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14084DOI Listing
July 2018
8 Reads

[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].

Rev Med Interne 2018 Nov 16;39(11):882-885. Epub 2018 Apr 16.

Service d'immunologie clinique et de médecine interne, centre national de référence des maladies auto-immunes rares, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France. Electronic address:

Introduction: Sinusoidal obstruction syndrome is a rare complication of autologous hematopoietic stem cell transplantation. This syndrome is mainly described following conditioning regiment with busulfan, cyclophosphamide and/or total body irradiation.

Case Reports: We report for the first time two cases of sinusoidal obstruction syndrome occurring lately after BeAM conditioning regiment (bendamustine, etoposide, aracytine, melphalan) for autologous stem cell transplantation in patients treated for malignant lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2018.03.009DOI Listing
November 2018

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Oncologist 2018 Sep 12;23(9):1103-1108. Epub 2018 Apr 12.

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R/R) CD33-positive acute myeloid leukemia (AML) in patients 2 years of age and older. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192608PMC
September 2018
19 Reads

[Treatment of four cases of Fanconi anemia by allogeneic hematopoietic stem cell transplantation with low intensity conditional regimen].

Zhonghua Xue Ye Xue Za Zhi 2018 Mar;39(3):231-235

Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, China.

To evaluate the efficiency and safety of low intensity conditional regimen for children with Fanconi anemia (FA) receiving allogenic hematopoietic stem cells transplantation (allo-HSCT). Four patients diagnosed as Fanconi anemia were enrolled in this study. One patient received HLA-identical sibling donor hematopoietic stem cell transplantation, two patients underwent unrelated donor matched (UD) HSCT, and one patient received unrelated cord blood transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.011DOI Listing

Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin.

Food Chem Toxicol 2018 May 7;115:63-72. Epub 2018 Mar 7.

Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 10, 10589 Berlin, Germany. Electronic address:

Acute liver toxicity, specifically in the form of hepatic veno-occlusive disease (HVOD), is known from reports on human poisonings following ingestions of 1,2-unsaturated pyrrolizidine alkaloids (PAs) containing herbs. Recently PA exposure via common foods contaminated via PA-producing plants raised concern, especially regarding the potential of genotoxicity and carcinogenicity. The health risks related to the estimated exposures to PAs from food were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2018.03.005DOI Listing
May 2018
7 Reads

Modified triangular hepatic vein reconstruction for preventing hepatic venous outflow obstruction in pediatric living donor liver transplantation using left lateral segment grafts.

Pediatr Transplant 2018 05 1;22(3):e13167. Epub 2018 Apr 1.

Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

HVOO can be a critical complication in pediatric LDLT. The aim of this study was to evaluate a modified triangular technique of hepatic vein reconstruction for preventing HVOO in pediatric LDLT. A total of 298 pediatric LDLTs were performed using a left lateral segment graft by 2 methods for reconstruction of the hepatic vein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13167DOI Listing
May 2018
7 Reads

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.

Biol Blood Marrow Transplant 2018 Jul 1;24(7):1471-1475. Epub 2018 Mar 1.

Hematology and Cellular Therapy Service, Saint Antoine Hospital, AP-HP, Paris, France; Université Pierre et Marie Curie (UPMC), Sorbonne Universités, Paris, France; INSERM, UMRs 938, Paris, France. Electronic address:

Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is a serious complication after hematopoietic stem cell transplantation (HSCT). SOS/VOD usually occurs within 3 weeks of HSCT, but the 2016 European Society for Blood and Marrow Transplantation diagnosis criteria have been revised to include late forms. Prophylactic use of defibrotide is recommended in the pediatric setting, but its value remains uncertain in the adult population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.02.015DOI Listing
July 2018
23 Reads

The involvement of Nrf2 antioxidant signalling pathway in the protection of monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats by (+)-catechin hydrate.

Free Radic Res 2018 Apr;52(4):402-414

a MOE Key Laboratory for Standardization of Chinese Medicines and Shanghai Key Laboratory of Compound Chinese Medicines , Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine , Shanghai , China.

Hepatic sinusoidal obstruction syndrome (HSOS) is a rare and life-threatening liver disease. (+)-Catechin is a natural dietary flavonol with high antioxidant capacity. This study aims to investigate the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant signalling pathway in the protection of (+)-catechin hydrate (CAT) against monocrotaline (MCT)-induced HSOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10715762.2018.1437914DOI Listing
April 2018
7 Reads

Re: Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.

Authors:
Sophie Cayet

Eur J Radiol 2018 03 2;100:155. Epub 2018 Feb 2.

Trousseau Hospital, Radiology, Avenue de la République, 37170, Chambray-lès-Tours, Tours, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2018.01.019DOI Listing
March 2018
3 Reads

Re: Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.

Eur J Radiol 2018 03 31;100:154. Epub 2018 Jan 31.

Department of Radiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine & Guangdong Provincial Hospital of Chinese Medicine, 111 Da De Lu, Guangzhou, Guangdong Province 510120, PR China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2017.12.016DOI Listing
March 2018
1 Read